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ABSTRACT

Bone resorption is dependent on the differentiation of osteoclast progenitor cells
into mature osteoclasts. The roles of receptor activator of NF -K8 ligand (RANKL), the
decoy receptor for RANKL (osteoprotegerin, OPG) and macrophage-colony stimulating
factor

(M-CSF), which are produced by osteoblasts or stromal cells, in

osteoclastogenesis are well established. RANKL and M-CSF are both considered to be
essential for osteoclastogenesis, while OPG is an inhibitor of RANKL actions. Tumor
necrosis factor (TNF-a) is a potent stimulator of bone resorption, especially under
inflammatory conditions.

However, the role of TNF-a in osteoclast proliferation,

differentiation and activation is still unclear. It has been reported previously that TNF-a
stimulates bone resorption indirectly via a primary effect on osteoblasts to increase
RANKL or decrease OPG. On the other hand, TNF- a has also been proposed to have
a direct action on the proliferation and differentiation of osteoclast progenitors [1].
In our current research, we use RA W 264.7 cells, a cell line of monocytemacrophage lineage. RAW 264.7 cells make M-CSF but do not express RANKL.
They can develop into osteoclasts if given RANKL. Our hypothesis is that TNF-a
cannot stimulate osteoclastogenesis without RANKL in RAW 264.7 cells but can
enhance the effects of RANKL on osteoclastogenesis via the induction of
cyclooxygenase-2 (COX-2) and production of prostaglandins.
The aims of this study are to determine ifTNF-a can stimulate osteoclastogenesis in
RAW 264.7 cells in the absence of RANKL and if TNF-a enhances the effect of added
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RANKL in this system VIa the TNF-a induction of prostaglandins produced by
cyclooxygenase (COX-2).
This project will help determine the role of TNF-a in osteoclast formation. This
will give us a better understanding of the processes involved in bone remodeling in

orthodontic tooth movement as well as in several diseases such as rheumatoid arthritis
and periodontitis.
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INTRODUCTION
Objective of Research
Previous research has shown that pro inflammatory cytokines, such as TNF-a and
interleukin-l (IL-l), playa role in the biologic processes involved in orthodontic tooth
movement. The inhibition of cytokine activity by the addition of soluble receptors
reduced the amount of tooth movement by 50% and also reduced the number of
osteoclasts [2].
Prostaglandins (PGs) are potent stimulators of bone resorption and are produced
largely by the induction of COX-2 in osteoblasts [21]. The effect of prostaglandins on
tooth movement has been studied extensively. Yamasaki et al [3] suggested that
orthodontic mechanical stress induced synthesis and secretion of prostaglandins (PGs)
by localized cells, which stimulated osteoclastic bone resorption. When PGEl or PGE2
were injected in the gingiva near the upper first molar in rats, osteoclasts and alveolar
bone resorption were observed. On the other hand, the administration of indomethacin,
an inhibitor ofPG production by both COX-l and COX-2, suppressed the appearance of
osteoclasts and bone resorption. Davidovitch et al [4] reported the involvement ofPGE2
in bone remodeling in orthodontically treated cats. Guinta et al [5] treated miniature
pigs with indomethacin and showed a significant decrease in the extent of resorption
surfaces histologically.
Cytokines, such as TNF-a and IL-l, have been shown to induce COX-2 expression
and PG production in osteoblasts and in cultured bone marrow cells [21] [6]. These
cytokines are potent inducers of bone resorption, and some of their effects on resorption
may be mediated via their induction of COX-2 and PGs [21]. Most of the regulation of
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osteoclastogenesis by cytokines and PGs is thought to occur via the induction of
RANKL in osteoblasts, which then binds to RANK receptor on cells of the
hematopoietic lineage.

However, it has been proposed that TNF-(l can induce

osteoclastogenesis by acting directly on cells of the hematopoietic lineage,
independently of RANKL. Therefore, the objective of this research is to determine if
TNF-(l can stimulate osteoclast formation via induction of COX-2 in cells of the
hematopoietic lineage.

Background

Osteoclasts

Osteoclasts are multinucleated giant cells that resorb bone. They develop from the
hemopoietic cells of the monocyte-macrophage lineage.

Major characteristics of

osteoclasts are (1) Tartarate-resistance acid phosphatase (TRAP) activity, (2) expression
of calcitonin receptors (CTR), (3) multinucleation, and (4) ability to resorb mineralized
bone.

TRAP is a resorptive enzyme identified in both the ruftled border of the

osteoclast membrane and the secretions in the resorptive space [7].
Osteoblasts/stromal cells are crucially involved in osteoclast development. Cell-tocell contact between osteoblasts/stromal cells and osteoclast progenitors is necessary for
induction of osteoclast differentiaton.[8]

Osteoclast differentiation involves several

major stages outlined in Figure 1.
Osteoclasts arise from hematopoietic stem cells (HSCs). HSCs give rise to colony
forming unit-granulocyte/macrophages (CFU-GMs). Macrophage/monocyte-colony
stimulating factor (M-CSF) stimulates the proliferation of CFU-GMs (osteoclast
precursors), which lack two osteoclast markers: TRAP and CTR. The mononuclear
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precursors differentiate into prefusion osteoclasts (positive for both TRAP and CTR)
with the stimulation of M-CSF and RANKL. The prefusion osteoclasts will further
differentiate by fusion to become multinucleated cells (with continuous stimulation of
M-CSF and RANKL). When these multinucleated cells become functional, they have a
ruffled border [9]. RANKL continues to play an important role in activating osteoclasts
by stimulating formation of the ruffled membrane [10].

RA W 264. 7 Cells

There is only one known clonal cell line that can give rise to osteoclasts in vitro.
The RAW 264.7 cell line is a functional macrophage cell line transformed by the
Abelson Leukemia Virus. These cells produce cytokines in response to lipopolysaccharide (LPS) and can make osteoclasts in response to RANKL [11-13]. Since they
produce M-CSF, it is not necessary to add M-CSF to cultures.

RANKL, M-CSF and Osteoprotegerin

RANKL is the ligand for the receptor activator of NF-KB.

It is also called

osteoprotegerin ligand (OPGL) [8]. It is a member of the TNF superfamily. It is a cell
surface molecule expressed by marrow stromal cells and osteoblasts, and by activated T
lymphocytes [14].

It is involved in bone metabolism by mediating osteoclast

differentiation, function and survival [11]. The discovery of RANKL helped establish
that osteoblasts/stromal cells support osteoclast differentiation primarily by serving as a
source of RANKL as well as M-CSF [10). Osteoblast/stromal cells express both MCSF and RANKL (membrane-bound and soluble), which bind to their respective
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receptors, c-fms and RANK, expressed on osteoclast precursors to stimulate osteoclast
formation.

In vitro, M-CSF and RANKL have been shown to be sufficient for

osteoclastogenesis [15].

Both RANKL knockout and RANK knockout mice show

features of osteopetrosis with a complete absence of osteoclasts in bone[16].
Osteoblasts/stromal cells also produce osteoprotegerin (OPG), a soluble decoy
receptor for RANKL. OPG inhibits RANKL function by competing with RANK for
RANKL [9].

TNF-a
TNF-a also modulates osteoclast formation and function [17]. TNF-a exerts its

function via two receptors.

TNF-a receptor 1 (TNFR1), or p55, contains a death

domain (DD), and the binding of TNF -a to TNFRI triggers programmed cell death
[18].

TNFR2, or p75, lacks a DD [9].

TNF-a signal pathways stimulate bone

resorption as well as inhibit bone formation. Binding ofTNF-a to its receptor activates
TNF-a receptor-associated death domain (TRADD), which in turn stimulates two well

known pathways: (1) activation of nuclear factor kappa B (NF-KB), Jun kinase (JNK),
p38 kinase, protein kinase C (PKC), and (2) activation of Fas activated death domain
(FADD), a protein that triggers the pro-apoptotic caspases and cell death.

These

pathways are not mutually exclusive, which makes the study if TNF -a action difficult
[17].

Unlike mice lacking RANKL or RANK, mice lacking TNF-a or its receptor do not
exhibit any bone defects [19], indicating that lNF-a mediated signaling is not essential
for skeletal development and physiologic bone remodeling. Inflammatory cytokines
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like TNF-a: and IL-l are secreted by macrophages and lor T-cells during pathologic
bone resorption, for example, in rheumatoid arthritis, periodontitis, and loosening of
implants [20].

Prostaglandins (PGs) and Cyclooxygenase-2 (COX-2)

Conversion of arachidonic acid (AA)--a 20 carbon fatty acid derived from the
cellular lipid bilayer--by cyclooxygenase (COX or prostaglandin endoperoxide
synthase) is the committed step in PG synthesis [21] (Figure 2). PGs are eicosanoids
produced by COX and exhibit numerous functions throughout the body.
There are two isoforms of COX, COX-l and COX-2, which have significant
sequence homology and identical catalytic activity, but their expression pattern is
markedly different. They have significant differences in mRNA splicing, stability and
translational efficiency, and they use different substrate pools [6]. The COX enzymes
are associated with two types of receptors: G-protein coupled receptors (transmembrane
receptors), and peroxisome proliferators-activated receptors (PPARs), which are
members of the nuclear receptor family of transcription factors. The most abundant PG
produced by osteoblasts, PGE2, is associated with four classes of receptors, EPI-EP4,
which are G-protein coupled receptors [21].
COX-l and COX-2 are produced throughout the human body. COX-l is
constitutively expressed in nearly all tissues (including osteoblasts) while COX-2 is
inducible. It was hypothesized that COX-2 is responsible for acute PG responses
associated with inflammation and pain, while COX-1 produces those prostanoids
needed for ongoing "housekeeping" functions, including maintenance of renal blood
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flow, platelet aggregation, and gastric cytoprotection. COX-2 is produced in response
to IL-1, TNF-a, TGF-a,

TGF-~,

parathyroid hormone, 1,25(OH)2D3 and mechanical

loading of bone [21]. The induction of COX-2 is transient, with a return to base-line
within 24-48 hours [6].
Non-selective,

non-steroidal

anti-inflammatory

drugs

(NSAIDs),

such

as

indomethacin, inhibit PG production by competing directly with AA for binding to the
cyclooxygenase catalytic site. Therefore, they are used to study the role of endogenous
PGs. NS-398 is a selective NSAID that inhibits COX-2 activity at a concentration of
0.01 JlM, but loses its selectivity at higher doses [21].
PGs appear to have a dual role in bone remodeling by enhancing both osteoclast
and osteoblast formation. Although PGs are known to be potent mediators of bone
resorption, their actions are complex. Osteoclastogenesis is enhanced because of an
increase in RANKL production. Induction of RANKL has been shown to be essential
for resorption by PGE2 [22], but PGE2 may also have some stimulatory effects on the
hematopoietic lineage as well [21]. On the other hand, PGE2 has also been shown to
inhibit the activity of mature osteoclasts [21]. Han et al [23] have shown that RANKL
can induce COX-2 expression, which results in production of PGE2 in RAW 264.7
cells. PGs also seem to increase osteoblast formation by recruiting osteoblast precursors
from a population of non adherent mesenchymal precursors in the bone marrow [24].
Thus, PGs can stimulate both resorption and formation and the balance of these
activities in vivo may determine whether bone is gained or lost.
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TNF-a and Osteoclastogenesis

In bone metabolism, it has been shown that numerous TNF family members
including RANKL, TNF-a, Fas ligand (FasL) and TNF-related apoptosis-inducing
ligand (TRAIL) play pivotal roles in the differentiation, function, survival and/or
apoptosis of osteoclasts [9]. TNF-a can induce RANKL production by osteoblasts or
marrow stromal cells and promote osteoclastogenesis. There is also the possibility that
ll\JF-a can induce osteoclastogenesis independent of RANKL by acting directly on
cells of the hematopoietic lineage.
Lam et al [14] showed that TNF-a targets both marrow stromal cells and
hematopoietic osteoclast precursors, but directly impacts the latter only in the presence
of permissive levels of RANKL. A pure population of murine osteoclast precursors
failed to undergo osteoclastogenesis when treated with TNF-a. However, TNF-a
dramatically stimulated differentiation in macrophages primed by less than 1% of the
amount of RANKL required to induce osteoclast formation. Administration of TNF-a
to RANK deficient animals failed to induce osteoclastogenesis, indicating that TNF-a
could not substitute for RANKL in physiological conditions. Macrophages isolated
from marrow cultures when treated with OPG were incapable of TNF-a induced
osteoclastogenesis. TNF-a potentiation of RANKL-primed osteoclastogenesis was
time-sensitive. TNF-a added concomitantly with the priming dose of RANKL failed to
induce osteoclast formation.

In contrast, when TNF-a was added 2-4 days after

RANKL priming, TNF -a induced osteoclastogenesis was maxima1. Outside of this
temporal window, TNF -a appeared to drive macrophage development along a
nonosteoclastogenic pathway.
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Zou et al [25] showed that TNF -u expression can be transcriptionally regulated by
RANKL. RANKL increased TNF-u expression by 8-fold and 4.5-fold in RAW 264.7
and bone marrow macrophages (BMMs), respectively.

RANKL increased TNF-u

transcription rate by 2.9-fold in RAW 264.7 cells. This transcriptional mechanism was
dependent on the NF-K8 sites in the TNF-u promoter. Hence, it is possible that some of
the effects ofRANKL might be mediated by RANKL-induced TNF-u.
Wei et al [26] found that TNF -u exerts its osteoclastogenic effect

Via

IL-l-

dependent and -independent signaling pathways and that the IL-l-mediated effect
involves, at least in part, RANKL-producing stromal cells. IL-l alone was incapable of
promoting osteoclast formation in macrophage/stromal cell coculture. However, IL-l
also directly targeted osteoclast precursors and promoted the osteoclast phenotype in a
TNF-independent manner in the presence of permissive levels ofRANKL (Figure 3).
On the other hand, Kobayashi et al [18] demonstrated that TNF-u can stimulate
osteoclast differentiation in the presence of M-CSF through a mechanism independent
of the RANKL-RANK interaction. They used bone marrow cells cultured for 3 days,
after which M-CSF dependent bone marrow macrophages (M-BMMs) were isolated
and treated with TNF-u. Osteoclast formation induced by TNF -u was inhibited by the
addition of antibodies against TNFRI (no TRAP-positive cells) or TNFR2 (markedly
reduced TRAP positive cells), but not by osteoprotegerin (OPG, a decoy receptor for
RANKL), nor the Fab fragment of anti-RANK antibody. Real time-polymerase chain
reaction (RT-PCR) showed that M-BMM expressed RANKL mRNA, but its levels were
low and not upregulated by adding TNF -u.
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Azuma et al [IJ using a cell culture similar to that used by Kobayashi et al [18],
found that TNF-a was a crucial differentiation factor for osteoclasts in the presence of
M-CSF, via the p55 TNF receptor. TNF-a directly induced the formation of TRAPpositive multinucleated cells (MNCs) in a dose-dependent manner at TNF-a
concentrations of 10 ng/ml and above. The number of TRAP-positive MNCs in TNF-atreated groups was about 50% of that in the soluble RANKL-treated groups. The bone
resorption activity of TNF-a induced NINCs was also lower than that of the RANKLinduced MNCs.
Zou et al [27] used cell cultures derived from three different mouse strains, Balb/c
and C57BLl6 (strains known to differ in inflammatory responses and cytokine
modulation) as well as RAW 264.7 cells. In the Balb/c cells, the following results were
seen:
1. TNF-a enhanced osteoclastogenesis in co-culture and in RANKL treated bone
marrow cells.

Antibodies to TNF -a and ll\lFRI inhibited RANKL induction of

osteoclastogenesis (also seen in RAW 264.7 cells).
2. TNF-a alone promoted osteoclastogenesis in the presence ofM-CSF (but was less
efficient than RANKL).
3. RANKL increased abundance of TNF-a mRNA and induced secretion of the
TNF-a (also seen in RAW 264.7 cells).
4. OPG inhibited RANKL induced osteoclastogenesis and TNF-a expression, but
not TNF-a activity.
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In the C57BLl6 cells, TNFR-1 antibodies did not affect RANKL-induced
osteoclastogenesis. Therefore, the authors concluded that there were different modes of
action ofRANKL in the two strains.
Hsu et al [11] showed that the RAW 264.7 cell line expressed high levels of RANK
mRNA. Treatment of RAW 264.7 cells with murine RANKL readily stimulated cell
differentiation into osteoclast-like TRAP-positive cells. They also showed that RANKL
induced JNK activation in RAW 264.7 cells. Activation of JNK was readily detectable
after 5 minutes ofRANKL exposure. NF-KB activation was not detectable in RANKLtreated RAW 264.7 cells. These data, strongly suggest lun kinase as a potentially
important osteoc1astogenic signal transducer.
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RESEARCH PLAN
Rationale

For tooth movement to occur, bone resorption has to occur on the compression side
and bone deposition on the tension side. Therefore, osteoclasts and osteoblasts play an
active role in tooth movement.

Under physiologic conditions, osteoblasts secrete

RANKL, which helps maintain function, but they do not express IL-l or TNF -0:.
However, under pathologic conditions or under the loading conditions necessary for
orthodontic tooth movement, these cytokines can be expressed. Since they are potent
stimulators of PG formation and bone resorption, they may contribute to the resorption
that permits tooth movement [28]. This goal of this project is to examine the role of
TNF-o: in the formation of bone resorbing cells.

Preliminary Data

Preliminary experiments were done in our lab on RAW 264.7 cells. The effects of
TNF-a and PGE2 on RAW 264.7 cells treated with RANKL (30 ng/ml) were observed.

The number of osteoclasts increased significantly when treated with TNF -0: or PGE2.
The effect of TNF -0: was dose-dependent (Figure 4).
A second experiment was conducted to see the effect of a COX-2 inhibitor (NS398) on RAW 264.7 cells treated with PGE2 + RANKL and TNF-o: + RANKL. There
was a significant reduction in the number of TRAP-positive cells with the addition of
NS-398 (Figure 5).
To take this one step further, we decided to determine if TNF-o: alone can stimulate
osteoclast formation. Previous literature has shown that it may [1, 18, 27]. However,
these experiments were done in bone marrow macrophages cultured with whole marrow
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cells for three days before they were isolated. Therefore these cells had been exposed to
RANKL prior to treatment with TNF-a. According to Lam et al [14], this priming with
RANKL is crucial for osteoclastogenesis with TNF-a. We propose the use of the RAW
264.7 cell line, which is a macrophage cell line that does produce RANKL and therefore
has no exposure to RANKL unless it is added.
This preliminary data and a review of the current literature led us to our current
hypothesis.

Hypothesis
1. ThTF -a cannot stimulate osteoclastogenesis by itself in RAW 264.7 cells but can
stimulate osteoclastogenesis in the presence of RANKL.
2. TNF-a can enhance the RANKL stimulated osteoclastogenesis by increasing COX2 expression and PG production in RAW 264.7 cells.

Specific Aims
Aim 1. To determine ifTNF-a alone can stimulate osteoclastogenesis in RAW 264.7
cells.
Aim 2. To determine ifTNF-a enhances RANKL induced osteoclastogenesis
Aim 3. To determine ifTNF-a induces COX-2 expression and PG production in RAW
264.7 cells
Aim 4. To determine the effect of inhibiting PG production by indomethacin (a general
inhibitor of both COX-l and COX-2 activity) and NS-398 (a selective inhibitor of
COX-2 activity) on TNF-a induced osteoclastogenesis.
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Materials and Methods
Materials
Tl~F-(l

was obtained from Roche Diagnostics (Indianapolis, IN). RANKL was

from R&D Biosystems (Minneapolis, MN).

NS-398 was from Cayman Chemical

Company (Ann Arbor, MI). Culture media were purchased from Gibco-BRL (Grand
Island, NY).

All other reagents were purchased from Sigma (St. Louis, MO) unless

otherwise specified.

Cell Culture

We used the RAW 264.7 murine macrophage cell line. Cells were plated at
concentrations of 1.2x104 cells/well or 6xl04 cells/well in 12 well dishes in (l-MEM
with 10% heat activated fetal calf serum (HIFCS), 100 V/ml of penicillin and 50 Jlg/ml
of streptomycin and cultured in a humidified atmosphere of 5% C02 at 37°c. We
started with an initial cell concentration of 6x 104 cells/well, but due to the large number
of osteoclasts produced, quantification was difficult and we reduced the concentration
to 1.2x104 cells/well. Cells were treated with RANKL (30 ng/ml), lliF-(l (10 ng/ml)
and RANKL + ThTF-(l. The vehicle was phosphate buffered saline (PBS) with 0.1 %
bovine serum albumin (BSA). Media were changed on day 2.
To inhibit COX-2 activity, cells were treated with indomethacin (1
398 (0.1

J1M) or NS-

J1M) and the vehicle, 0.1 % ethanol, was added to control cultures.

Tatrate Resistance Acid Phospatase Staining

Cells were fixed at the end of culture with 2.5% glutaraldehyde. A Leukocyte
Acid Phosphatase Kit (Sigma) was used to stain for tartrate resistant acid phospahatase
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(TRAP, a marker of osteoclasts) following the manufacturer's instructions. The TRAP
positive multinucleated cells (MNCs), with 3 or more nuclei, were counted under the
microscope at lOX magnification. Media were collected from each well, placed in
dishes covered with parafilm securely and stored at -20°C for PGE2 assays.

PGE2 Assay

Medium was removed from cultured cells and PGE2 accumulation was
measured on days 2, 3 and 4 using enzyme immunoassay kits. The experiment was
repeated three times with three different enzyme immunoassay kits following the
manufacturer's instructions: (1) EIA Cayman (monoclonal), Ann Arbor, MI.

The

detection range was 7.8-1000 pg/mL

The

(2) Cayman Express, Ann Arbor, MI.

detection range was 15.6 pg/ml to 2000 pg/mL (3) Assay Designs, Ann Arbor, MI. The
detection range was 38.7 pg/ml to 2600 pg/ml (0.11 to 7.4 nM).

RNA Extraction, Real Time-PeR

Cells were plated in 12-well dishes at a concentration of 1.2xl04 cells/well and
treated with vehicle, RANKL (30 ng/ml), TNF-a (10 ng/ml) or RANKL + TNF-a.
Three wells of cells were pooled for one sample. Total RNA was extracted using Trizol
(Invitrogen, Carlsbad, California) in accordance with the manufacturer's directions. 2-5
I!g of total RNA was converted to cDNA by the High Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA) following manufacturer's instructions.
Quantitative PCR for gene expression was performed in 96-well plates using Assayson-Demand Gene Expression system (Applied Biosystems). Glyceraldehyde 3phosphate dehydrogenase (GAPDH) served as the endogenous control. Each sample

17

was amplified in duplicate. Primers were tested for equal efficiency over a range of
target gene concentrations. The PCR reaction mixture (20 JlL/well including 2X
TaqMan Universal PCR Master Mix, 20X Assays-on-Demand Gene Expression Assay
Mix and 40 ng of cDNA) was run in Applied Biosystems ABI Prism 7300 Sequence
Detection System instrument utilizing universal thermal cycling parameters. A pool of
reversed transcribed samples was the calibrator. We used the relative standard curve
method, which sets standard curves for the target gene and endogenous control
(GAPDH) by serially diluting total RNA, normalizes the amount of the target gene
calculated from the standard curve to the amount of the control gene calculated from the
standard curve, and compares the fold induction to the calibrator sample.

Statistical Analysis

All values are depicted as the mean ± standard error of the mean (SEM).
Statistical analysis was performed using SigmaStat® for Microsoft Windows®, version
2.03 (San Rafael, CA). To compare multiple treatment groups, differences were
examined by one-way analysis of variance (ANOVA) followed by the post hoc
Bonferroni's test.
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RESULTS

SPECIFIC AIM #1: To determine if TNF-a alone can stimulate osteoclustogenesis in
RA W 264.7 cells
No osteoclasts were observed in the control cultures. In the wells treated with
TNF -a alone, there appeared to be an increase in the number of TRAP stained
mononuclear cells on day 3 of the culture as compared to the control. The mononuclear
cells also appeared to aggregate to form clusters. Osteoclast formation, defmed as
TRAP positive MNCs, began on day 4. The microscopic images of the wells showed
large, MNCs (2: 3 nuclei) that were stained purple due to TRAP activity (Figures 6 and
7). This experiment was repeated five times. In three of the experiments, the peak in
TNF-a induced osteoclast formation was on day 4 (Figures 8 and 9). In the remaining
two experiments, the peak in the number of osteoclasts was observed on day 5 (Figure
10). There was a large variation in the number of TNF-a induced osteoclasts in the
different experiments. For example, in one experiment, there were 189 ± 5 osteoclasts
on day 4 and 462 ± 33 osteoclasts on day 5 (Figure 10, expt 5). In another experiment,
there were 7 osteoclasts on day 4 and 1.5 ± 0.5 on day 5 (Figure 9). The reason for this
variability is unclear. There are several possibilities: 1) changes in the phenotype with
the passage of the cells, 2) unintended differences in the plating densities, and 3)
decreased efficacy of the TNF-a stock over time.

SPECIFIC AIM #2: To determine if TNF-a can enhance RANKL induced
osteoclastogenesis
When the RAW 264.7 cells were treated with RANKL + TNF-a, there was a
statistically significant increase in the number of osteoclasts on day 3 (p<0.05) and on
day 4 (p<0.01) as compared to RANKL alone (Figures 7 and 11). This experiment was
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repeated 4 times with similar results. On day 5, there was a decrease in the number of
osteoclasts with RANKL + TNF -a as compared to RANKL alone. However, this
difference was not statistically significant. Examination of the wells on day 5 showed
the appearance of ghost cells, which lacked the TRAP positive staining as well as an
intact cell membrane (Figure 7).

SPECIFIC AIM #3: To determine if TNF-a induces COX-2 expression and
prostaglandin production in RA W 264.7 cells
Media from the cell culture experiments were analyzed for PGE2 production via
Enzyme Immunoassay (EIA). The experiment was repeated three times with three
different assay kits. There was an n=l in each treatment group.
1. Cayman EIA (7.8

1000 pg/ml): The PGE2 levels were below the detection

range in the control cultures. Treatment with TNF-a increased PGE2
accumulation in the media (the values ranged from 17.8 to 78.6 pg/ml). (Table
1).

2. Cayman Express (15.6 - 2000 pg/ml): The PGE2 levels were below the
detection range on days 2 and 4 of the control cultures. On day 3, PGE2 level
was measured at 20.9 pg/ml, which is barely detectable. Treatment with TNF-a
increased PGE2 accumulation in the media by 5-fold (105.7 pg/ml) or more as
compared to the control (Table 2).
3. Assay Design ErA kit (detection range 38.7

2600 pg/ml): The PGE2 levels

were below the detection range in the control cultures. Treatment with TNF-a
increased PGE2 accumulation in the media and the values ranged from 77.85 to

20
439.6 pg/ml (the assay was repeated twice on each sample and the given values
are a mean of the two readings) (Table 3).
There was a consistent trend in all three assays of increasing PGE2 levels from day 2
through day 4 when treated with TNF -a. These assays were also performed on media
from cells treated with TNF-a + indomethacin. Levels of PGE2 in the media from
indomethacin treated cells were below the detectable range.
Real time PCR conducted on day 3 showed a small induction of COX-2 mRNA
when RAW 264.7 cells were treated with TNF-a (10 ng/ml). This increase in COX-2
expression was statistically significant (p<O.Ol) (Figure 12). However, since COX-2 is a
transiently expressed gene, we may have missed a larger induction earlier in culture.

SPECIFIC AIM #4: To determine the effect of inhibiting PG production with
indomethacin and NS-398 on TNF-a induced osteoclastogenesis
The results of adding either a nonselective COX inhibitor (indomethacin) or a
selective COX-2 inhibitor (NS-398) to the RAW 264.7 cell cultures were very similar.
When either indomethacin (Indo, 1

~)

or NS-398 (0.1

J.1M) were added to the cells,

there was either an increase or no change in osteoclast number. On day 3, RANKL +
Indo (820±25 cells/well) showed a significant increase compared to RANKL alone
(507±18 cells/well) (Table 4 and Figure 13). Similarly, on day 3, TNF-a + NS-398
(4.3±0.3 cells/well) was significantly greater than TNF-a alone (1.3±0.9 cells/well) as
was RANKL + TNF-a + NS-398 (343.3±13 cells/well) compared to RANKL + TNF-a
(255±21 cells/well) (Table 5 and Figure 14). Neither of these inhibitors of PG
production caused a decrease in the number ofMNCs formed, except on day 5. On day
5, when treated with TNF-a + Indo as compared to TNF-a, the osteoclast number
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decreased by a mean of 168 cells. Similarly, in the TNF-a + NS398 treatment group,
there was a mean decrease of 63 in the number of osteoclasts as compared to TNF-a
alone. With RANKL+TNF-a + NS 398, the osteoclast number decreased by 111 as
compared to RANKL + TNF-a. However, none of these decreases were statistically
significant. All other treatments, showed either a significant stimulatory effect or no
change in osteoclast number when either indomethacin or NS-398 were added to the
different treatments (Tables 4 and 5, Figures 13 and 14).
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DISCUSSION

Since RAW 264.7 cells do not make RANKL, the presence of TRAP stained
MNCs in RAW 264.7 cells treated with 1NF-a indicates that 1NF-a alone can induce
osteoclastogenesis by acting on the hematopoietic lineage. There was an increase in the
number of TRAP stained mononuclear cells on day 3, and they appeared to aggregrate
into clusters of cells. This could suggest the beginning of the transformation into
osteoclasts, as multiple mononuclear cells fuse together to form MNCs (a key
characteristic of osteoclasts). This observation is consistent with the recent studies of Li
et al [29] and Yao et al [30] that concluded 1NF-a could increase the proliferation of
osteoclast precursors in bone marrow by enhancing c-Fms (the receptor for M-CSF)
expression in the osteoclast progenitor pool. These progenitors would then have a
greater proliferative response to M-CSF. Hence, it would be interesting to quantify the
cell numbers and examine the mRNA and protein expression of c-Fms in RA W 264.7
cells treated with/without 1NF -a.

It would also be interesting to examine the

expression of M-CSF and the response to added M-CSF in cells treated with/without
1NF-u.
These authors (Li; Yao) found that RANKL was necessary to produce mature
multinucleated osteoclasts in their bone marrow culture system. On the other hand,
consistent with our data, Zou et al [27] reported that 1NF-u alone can induce the
formation of TRAP positive MNCs in RAW 264.7 cells. However, no RAW 264.7 data
were actually shown in their paper, and there was no report of whether or not the TRAP
positive ]vINCs formed in response to 1NF-u in RAW 264.7 cells could resorb bone. A
recent article by Hotokezaka et al [31] suggests that 1NF-a alone can induce the fusion
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of TRAP positive mononuclear cells (derived from RAW 264.7 cells) into TRAP
positive MNCs through the TNF-a receptors. Subsequent activation of signaling
pathways involving PI3K, Src, ERK and JNK molecules was required for the cell
fusion. In the future we will need to demonstrate that our TRAP positive MNCs are
truly mature osteoclasts by placing them on bone slices and showing that they can form
pits.
TNF -a was not as effective as RANKL in our model. The total number of TRAP
positive MNCs formed after treatment with TNF-a was always lower than the number
formed with RANKL alone in the same experiment. Similar results were found in the
study by Azuma et al [1] where the number of TRAP-positive MNCs in TNF-a-treated
groups was about 50% of that in the soluble RANKL-treated groups. Thus, it seems
likely that under normal physiologic conditions, the RANKL pathway for
osteoclastogenesis would predominate. Although we did demonstrate that a significant
increase in the number of osteoclasts with RANKL + TNF-a as compared to RANKL
alone, we must do more studies to determine whether this effect is additive or
synergistic. Our previous experiments indicated 30 ng/m! ofRANKL produces maximal
osteoclastogenesis in RAW 264.7 cells. Hence, the observation that TNF-a can increase
the effects of 30 ng/ml RANKL on osteoclastogenesis suggests that the two agonists
work in part by independent pathways. The decrease in osteoclast number seen on day 5
with RANKL + TNF-a as compared to RANKL alone is possibly due to an acceleration
of osteoclast formation, resulting in an earlier peak of osteoclast formation in the
combination treatment, followed by normally occurring cell death, or perhaps by
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increased apoptosis/cell death with the joint treatment. This could be studied by doing
more precise time courses and using stains to demonstrate the apoptotic cells.
One of the ways that TNF -a may enhance the effect of RANKL is to upregulate
the RANK receptor.

The combination of TNF-a and RANKL was found to

synergistically upregulate RANK expression in osteoclast precursor cells isolated from
marrow cultures by Zhang et al [32]. We can use leftover RNA extracted from our
cultures to investigate this possibility in RAW 264.7 cells. These authors also found
that that TNF-a enhanced RANKL induced osteoclastogenesis by interaction of the
signaling pathways downstream from the RANK and ThTF -a receptor 1 and that these
coupling effects were dependent on the TNF-a receptor 1.
Although RAW 264.7 cells are not supposed to express RANKL, we considered
the possibility that TNF-a could induce RANKL in these cells. We tried to measure
RANKL mRNA by real time PCR but it was undetectable (data not shown). Other
possible experiments to confirm that RANKL was not involved in the effects of TNF-a
would be to see what happened to the effects ofTNF-a after treating cultures with OPG,
knocking down receptors for TNF-a with small interfering RNAs, or using specific
blocking antibodies for TNF-a.
It is also possible that RANKL acts in part to increase osteoclastogenesis via

induction ofTNF-a. For example, Nakao et al [33] have shown that RANKL stimulates
TNF-a expression and that formation of TRAP positive MNCs in RAW 264.7 cultures
were reduced by treatment with specific blocking antibodies to TNF-a or to TNF-a
receptor 1. We address this issue by using RNA extracted from our cultures to measure
TNF-a mRNA levels after treatment with/without RANKL +/- TNF-a.
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We found increased PGE2 in the media collected from the wells treated with
TNF -a. This suggests that TNF -a stimulates PGE2 production and is consistent with
studies from Han et al

[23]. These authors showed that RANKL transcriptionally

upregulated COX-2 expression in RAW 264.7 cells but did not show effects of
inhibiting COX-2 activity on osteoclast formation in these cells (only in bone marrow
derived osteoclasts). In our studies, the medium PGE2 increased from day 2 to day 4,
suggesting that the peak in PGE2 production coincided with the peak in osteoclast
formation. However, in contrast to our original hypothesis, we found that inhibiting PG
production with NSAIDs, NS-398 or indomethacin, did not decrease osteoclast
formation in any of the treatment groups: RANKL, ll\JF-a, or the combination. In fact,
in many cases, addition of NSAID significantly stimulated the formation of TRAP
positive MNCs.
We had expected that inhibiting PG production would decrease the effect of
RANKL since it has been reported that RANKL-induced COX-2 expression and PG
production are required for maximal effects of RANKL stimulated osteoclastic
differentiation by Han et al [23]. However, these investigators only showed the effects
of inhibiting COX-2 activity on RANKL-induced osteoclastogenesis in bone marrow
derived osteoclast cultures and not in RAW 264.7 cells. It is likely that the bone
marrow derived osteoclast cultures also contained some osteoblasts or stromal cells and
perhaps the presence of these cells had some influence on the effects of the NSAIDs.
PGs are known to increase osteoblast formation by recruiting osteoblast precursors from
mesenchymal precursors in the bone marrow stromal cultures [24].
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There are other studies showing that PGs can inhibit osteoclast formation in
cultures containing only cells of the hematopoietic lineage.

For example, a recent

article by Akaogi et al [34] showed that PGE2 could suppress osteoclastogenesis by
inhibiting IL-17-induced TNF-a expression in macrophages. Ono et al [35] showed that
PGE2 had biphasic effects on spleen cell cultures from mice.

Spleen contains

hematopoietic lineage cells but no osteoblast lineage cells and spleen cells can
differentiate into osteoclasts if given RANKL and M-CSF. In these cells, PGE2 had an
initial inhibitory effect on osteoclastogenesis, followed by a stimulatory effect. The
stimulatory effect was postulated to be due to factors secreted by T cells in the spleen
cultures. Take et al [36] have also reported that PGE2 inhibits osteoclast formation in
cultures of cells prepared from human peripheral blood mononuclear cells (PBMCs).
These cultures do not contain any osteoblasts or stromal cells and they were selected to
contain no T cells as well. They also found that NS-398 enhanced osteoclast formation
when these PBMCs were co-cultured with a clonal osteoblast cell line isolated from an
osteosarcoma. It is possible that PGs have different effects on different stages of the
hematopoietic lineage or that effects will vary depending on other cells in the
environment.
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SIGNIFICANCE OF THE RESULTS

This study will give us a better understanding of the role of TNF -(1 in
osteoclastogenesis and bone remodeling and its mechanism of action via COX-2 and
prostaglandin production. This is turn will help us better understand the therapeutic
ability of nonselective NSAIDS and selective COX-2 inhibitors. It will shed some light
on the causes of several metabolic bone diseases caused by abnormal osteoclast
recruitment and functions such as osteopetrosis, osteoporosis, metastatic bone disease,
Paget's disease, rheumatoid arthritis and periodontal disease [10]. In addition, it will
give orthodontists greater insight into the mechanisms involved in stimulation and
inhibition of tooth movement. This in turn could improve the quality and efficiency of
treatment.
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TABLES
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TREATMENTS

DAY 2

DAY 3

DAY 4

Control

ND

ND

ND

ND

ND

ND

17.8

59.2

78.6

ND

ND

ND

+ Indo
TNF-a

+Indo

Table 1: PGE2 producti.on (pg/ml) on days 2, 3 and 4 measured by
Cayman EIA. RAW 264.7 cells were treated with vehicle (Control) and
TNF- a (10 ng/ml). Cultures were also treated with / without indomethacin
(1 J1M), a nonselective inhibitor of both COX-1 and COX-2 activity.
Units: pg/ml, Detection Range: 7.8 to 1000 pg/ml, ND non detectable
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Groups

Day 2

Day 3

Day 4

Control

ND

20.9

ND

ND

23.0

26.9

68.2

105.7

120.0

20.9

39.4

38.7

+Indo
TNF-a
+Indo

Table 2: PGE2 production (pg/ml) on days 2, 3 and 4 measured by
Cayman Express. RAW 264.7 cells were treated with vehicle (Control)
and TNF-a (10 nglml). Cultures were also treated with / without
indomethacin (1 flM), a nonselective inhibitor of both COX-I and COX-2
activity.
Units: pglml, Detection Range: 15.6 to 2000 pg/ml, ND non detectable
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GrOUI!S

Day 2

Day 3

Day 4

Control

ND

ND

ND

ND

ND

ND

77.85

336.2

439.6

ND

ND

ND

+Indo
TNF-a

+Indo

Table 3: PGEz production (pg/ml) on days 2, 3 and 4 measured by
Assay Design EIA Kit. RAW 264.7 cells were treated with vehicle
(Control) and TNF-a (10 ng/mI). Cultures were also treated with! without
indomethacin (l ~), a nonselective inhibitor of both COX-l and COX-2
activity.
Units: pg/ml, Detection Range: 38.7 to 2600 pg/ml, ND - non detectable
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DAY 4

DAYS

0

0

0

0

0

0

4.7± 0.9

189.3 ± 4.9

462.3±33.0

0.7

240.7 ± 0.7

294.7±13.0

507.3± 17.8

949.0 ± 95.6

916.0±40.5

820.0± 25.1 a

1130.3±60.8

986.0±7S.l

1370.7 ± 5.2

1606.7±45.3

769.3±20.2

1440.3±102.2

''''''.0±74.8

737.7±13.6

TREATMENTS

DAY 3

Control
+Indo
TNF-a
+Indo
RANKL
+Indo
RANKL+ TNF-a
+Indo

11

i

Table 4: Effect of Indomethacin on osteoclast formation. RAW 264.7
cells were treated with vehicle (Control), TNF- u (10 ng/ml), RANKL (30
ng/ml) , or the combination of RANKL + TNF- u. Cultures were also
treated with / without indomethacin (1 ~), a nonselective inhibitor of
both COX-l and COX-2 activity. Numbers are means ± SEM for n 3 wells
of cells.
aSignificant stimulatory effect of indomethacin, p <0.01.
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DAY 3

DAY 4

DAYS

0

0

0

0

0

0

1.3 ± 0.9

53.7 ± 6.4

. ±18.6

4.3 ± O.3 a

62.3 ± 3.2

189.3±15.0

13.8

897.7 ± 79.8

843.3±31,4

150.7 ± 14.4

1140.7±93.1

867.3±24.9

1429.3±93.0

636.0±52.1

1420.0±124.2

525.7±39.5

Control
+ NS398
TNF-a
+ NS398
RANKL
+ NS398

110.3

21.4

RANKL +TNF-a
+ NS398

343.3

2.8 a

Table 5: Effect of NS398 on osteoclast formation. RAW 264.7 cells were
treated with vehicle (Control), TNF- a (10 ng/ml), RANKL (30 ng/ml), or
the combination of RANKL + TNF- a. Cultures were also treated with /
without NS398 (0.1 11M), a selective COX-2 inhibitor. Numbers are means
± SEM for n=3 wells of cells.
aSignificant stimulatory effect of indomethacin, p <0.05.
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Figure 4: Effects of TNF -(1 and PGE2 on osteoclastogenesis in
RAW 264.7 cells treated with 30 ng/ml RANKL. Cells were
cultured for 5 days in the presence of RANKL plus treatments as
indicated. There was a significant increase in TRAP positive
multinucleated cells (MNCs) when the cells were treated with
PGE z (1 ~) or with TNF-a (1 and 10 ng/ml).
aSignificantly different from control, P< 0.01;
bSignificantly different from control, P< 0.05
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Figure 5: Effects of inhibiting PGE 2 production by
NS-398 (0.1 ~) on TNF-ex induced osteocIastogenesis
in RAW 264.7 cells treated with 30 ng/ml RANKL.
Cells were treated for 5 days. NS-398, a selective COX-2
inhibitor, inhibited the induction of TRAP positive
multinucleated cells (MNCs) stimulated by PGE2 and
TNF-a.
aSignificantly different from control, P< 0.01
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d3

Control

d4

d5

(

RANKL

TNF-a

RANKL+
TNF-a

Figure 6: TRAP staining following treatment with
RANKL (30 ng/ml), TNF-u (10 nglml) or RANKL + TNFu. Cells were treated for the number of days indicated and
stained with TRAP. Dishes were scanned into Adobe
Photoshop. TRAP positive cells appear pink/purple. With
both RANKL and RANKL + TNF -(1, there was an increase
in TRAP positive cells on days 3 and 4. Although not
apparent in this picture, "ghost cells" (structures that appear
to be dead TRAP positive cells) appeared on day 5. With
TNF -(1 alone, TRAP positive cells are visible on day 5.
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Day 3

Day 4

DayS

Vehicle

TNF-a;

RANKL

RANKL
+
TNF-a;

Figure 7: Microscopic images of osteoclast formation
following treatment with TNF-u (10 ng/ml), RANKL (30
ng/ml) or RANKL + TNF -u. Mononuclear cells increased
in number in cultures treated with TNF -u alone on day 3 and
TRAP positive NINCs appeared on days 4 and 5. The
combination of RANKL + TNF -u increased the number of
TRAP positive NINCs, compared to RANKL alone, on days
3 and 4. Ghost cells appeared on day 5 in RANKL treatment
groups.
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Figure 8: Quantification of TRAP positive MNCs on
days 3, 4 and 5 in RAW 264.7 cell cultures treated with
TNF-a (10 ng/ml) alone.
aSignificantly different from control, p<O.Ol.

43

Expt3

10

a
8
Q,)

~

tn

6

(J

4

:E
+
a..

2

t-

0

z

«
0::

3d

4d

o

5d

CONTROL
TNF-a

Figure 9: Quantification of TRAP positive MNCs on
days 3, 4 and 5 in RAW 264.7 cell cultures treated
with TNF-(1 (10 ng/ml) alone.
aSignificantly different from control, p<O.O 1.
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Figure 10: Quantification of TRAP positive MNCs on
days 3, 4 and 5 in RAW 264.7 cell cultures treated with
TNF-a (10 ng/ml) alone. In some experiments TRAP
positive MNC number peaked later than day 4.
aSignificantly different from control, p<O.Ol.
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Figure 11: Effect of TNF-a (10 ng/ml) on RANKLinduced osteoclastogenesis in RAW 264.7 cells on
days 3, 4 and 5. On days 3 and 4 of cell culture, there
were a significantly greater number of TRAP positive
MNCs formed with RANKL+ TNF-a compared to
RANKL alone.
aSignificantly different from control, P< 0.01
bSignificantly different from control, P< 0.05
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aSignificantly different from control, p <0.01
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Figure 13: Effect of Indomethacin on osteoclastogenesis
in RAW 264.7 cells
Bars are means ± SEM for 3 samples.
aSignificant stimulatory effect of indomethacin, p <0.01
bSignificant stimulatory effect of indomethacin, p <0.05
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